Inflammatory bowel diseases during the coronavirus pandemic: potential risks and ways to reduce them

Cover Page

Cite item

Full Text

Abstract

This review is devoted to the current issues on management of the patients with inflammatory bowel diseases during the new coronavirus SARS-CoV-2 pandemic. Since March 2020, the World Health Organization with the support of international gastroenterological associations has launched a project for monitoring and reporting outcomes of COVID-19 occurring in inflammatory bowel diseases patients — SECURE-IBD aimed to define the impact of COVID-19 on patients with inflammatory bowel diseases and how factors such as age, comorbidities, and inflammatory bowel diseases treatments influence COVID outcomes (www.covidibd.org). According to the data of this Registry, no higher incidence of SARS-CoV-2 in patients with inflammatory bowel diseases compared to the general population has been reported. However, active inflammation, severe disease course, the induction period of immunosuppressive therapy and the use of systemic steroids are unfavorable predictors of severe COVID-19 infection course in case of inflammatory bowel diseases.

About the authors

Igor G. Bakulin

North-Western State Medical University named I.I. Mechnikov

Email: igbakulin@yandex.ru
ORCID iD: 0000-0002-6151-2021
SPIN-code: 5283-2032
Scopus Author ID: 6603812937
ResearcherId: P-4453-2014

Dean of the medical faculty, Professor, doctor of medical Sciences, head of the Department of propaedeutics of internal diseases of gastroenterology and dietetics named after S. M. Rys

Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015

Maria I. Skalinskaya

North-Western State Medical University named I.I. Mechnikov

Author for correspondence.
Email: mskalinskaya@yahoo.com
ORCID iD: 0000-0003-0769-8176
SPIN-code: 2596-5555

Associate proffessor of the Chair of the Propedeutics of Internal Diseases, PhD Gastroenterology and Dietology n.a. S.M. Riss

Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015

Ekaterina V. Skazyvaeva

North-Western State Medical University named I.I. Mechnikov

Email: eskazyvaeva@yandex.ru
ORCID iD: 0000-0002-8563-6870
SPIN-code: 5882-1152

доцент, доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М.Рысса к.м.н.

Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015

Maria S. Zhuravleva

North-Western State Medical University named I.I. Mechnikov

Email: ms_zhuravleva@mail.ru
ORCID iD: 0000-0003-4838-5707
SPIN-code: 5107-3034

доцент кафедры пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М.Рысса к.м.н.

Russian Federation, 41, Kirochnaya street, Saint-Petersburg, 191015

References

  1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. https://doi.org/10.1016/s0140-6736(20)30566-3.
  2. Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020. https://doi.org/10.1097/CM9.0000000000000774.
  3. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107(9):1409-1422. https://doi.org/10.1038/ajg.2012.218.
  4. Jones GR, Lyons M, Plevris N, et al. IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. Gut. 2019;68(11):1953-1960. https://doi.org/10.1136/gutjnl-2019-318936.
  5. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. https://doi.org/10.1136/gutjnl-2019-318484.
  6. Fiorino G, Lytras T, Younge L, et al. Quality of care standards in inflammatory bowel diseases: a European Crohn’s and Colitis Organisation (ECCO) position paper. J Crohns Colitis. 2020. https://doi.org/10.1093/ecco-jcc/jjaa023.
  7. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020. https://doi.org/10.1183/13993003.00547-2020.
  8. Garg M, Royce SG, Tikellis C, et al. Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? Gut. 2020;69(5):841-851. https://doi.org/10.1136/gutjnl-2019- 318512.
  9. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020. https://doi.org/10.1053/j.gastro.2020.02.055.
  10. Маев И.В., Шелыгин Ю.А., Скалинская М.И., и др. Патоморфоз воспалительных заболеваний кишечника // Вестник Российской академии медицинских наук. – 2020. – Т. 75. – № 1. – С. 27–35. [Maev IV, Shelygin YA, Skalinskaya MI, et al. The pathomorphosis of inflammatory bowel diseases. Annals of the Russian academy of medical sciences. 2020;75(1):27-35. (In Russ.)]. https://doi.org/https://doi.org/10.15690/vramn1219.
  11. Бакулин И.Г., Авалуева Е.Б., Сказываева Е.В., и др. Воспалительные заболевания кишечника. Карманные рекомендации для врачей по ведению пациентов с воспалительными заболеваниями кишечника. – М.; СПб., 2018. – 48 с. [Bakulin IG, Avalueva EB, Skazyvaeva EV, et al. Vospalitel’nye zabolevaniya kishechnika. Karmannye rekomendatsii dlya vrachey po vedeniyu patsientov s vospalitel’nymi zabolevaniyami kishechnika. Moscow; Saint Petersburg; 2018. 48 p. (In Russ.)]
  12. Wisniewski A, Kirchgesner J, Seksik P, et al. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United European Gastroenterol J. 2019:205064061988976. https://doi.org/10.1177/2050640619889763.
  13. Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225): 683-684. https://doi.org/10.1016/s0140-6736(20)30361-5.
  14. Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5:18. https://doi.org/10.1038/s41392-020-0127-9.
  15. Papamichael K, Karatzas P, Mantzaris GJ. De-escalation of Infliximab maintenance therapy from 8- to 10-week dosing interval based on faecal calprotectin in patients with Crohn’s disease. J Crohns Colitis. 2016;10(3):371-372. https://doi.org/10.1093/ecco-jcc/jjv206.
  16. Hoentjen F, Haarhuis BJ, Drenth JP, de Jong DJ. Elective switching from infliximab to adalimumab in stable Crohn’s disease. Inflamm Bowel Dis. 2013;19(4):761-766. https://doi.org/10.1097/MIB.0b013e3182802ae1.

Copyright (c) 2020 Bakulin I.G., Skalinskaya M.I., Skazyvaeva E.V., Zhuravleva M.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies